

Product Data Sheet

Product Name: SHP1-IN-2

Cat. No.: GC81519

Chemical Properties

Cas. No.


Formula $C_{13}H_{10}ClN_3O_3S_2$ M.Wt 355.82

Solubility DMSO: 100 mg/mL (281.04 mM; Need ultrasonic) Storage Store at 4°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

SHP1-IN-2 is a selective and orally active SHP1 inhibitor. SHP1-IN-2 covalently binds to Cys480 of

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

SHP1. SHP1-IN-2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1-IN-2 blocks tumor progression in a syngeneic cancer model by activating natural killer cells and cytotoxic CD8 + T cells, along with reduced T cell I. SHP1-IN-2 can be used for cancer-related research [1].

In Vivo, SHP1-IN-2 (M029) (25 mg/kg, 100 mg/kg; once daily) significantly suppresses tumor growth in MC38 colon cancer syngeneic mouse models^[1]. SHP1-IN-2 (25 mg/kg; once daily) increases infiltration and activation of NK cells and CD8+ T cells, reduces the proportion of PD-1+ TIM3+ exhausted T cells in MC38 tumor tissues, shows no obvious toxicity or body weight loss in tumor-bearing mice, and loses antitumor efficacy in CD8+ T cell-depleted mice and nude mice^[1].

In Vitro, SHP1-IN-2 (M029) (up to 50 μ M; 24-72 h) shows no obvious cytotoxicity in Jurkat T, HEK293, MC38, EO771, B16-F10, and Raw264.7 cells^[1]. SHP1-IN-2 (0-20 μ M; Anti-CD3 Antibody (OKT-3) stimulation for 10 min) enhances the phosphorylation of LCK, PLC γ , and ERK1/2 and promotes IL-2 production in TCR-stimulated Jurkat T cells^[1].

References:

[1]. Qu Z, et al. Discovery of a First-in-Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity. Angew Chem Int Ed Engl. 2026;65(7):e25126.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA